Medical technology consulting services
Quint Healthcare helps medical technology, diagnostic and digital health organisations turn technically promising products into clinically credible, evidence-based and implementable solutions.
The work begins where clinical, regulatory and commercial questions can no longer be solved independently: an intended purpose shapes classification and evidence; evidence affects reimbursement and adoption; clinical workflow determines whether an approved product is actually used.
Choose the question you need to answer
| Your current question | Recommended service |
|---|---|
| Is our clinical evaluation defensible under MDR or IVDR, and how should we address the gaps? | EU regulatory affairs and clinical evaluation |
| What evidence is necessary, and how should a credible validation study be designed and managed? | Clinical evidence and medical device validation studies |
| Why is a product that works elsewhere not gaining traction in Germany or Europe? | European market access and clinical adoption |
| Who owns the clinical need, intended purpose, claims and medical risk within our organisation? | Medical product strategy and fractional medical leadership |
| Which European funding route fits, and how should the consortium and proposal be built? | European funding and consortium development |
| How will a digital pathology or intraoperative imaging technology enter the real clinical workflow? | Focus area: digital pathology and intraoperative imaging |
| How can a healthcare innovation team improve alignment, collaboration and decision-making? | Team development for healthcare innovation |
What connects the services
Medicine before documentation
A clinical evaluation, study protocol or market plan is only as good as the medical assumptions beneath it. Quint Healthcare examines the clinical need, user, patient population, workflow and claim before building the document or programme around them.
Evidence designed for more than one audience
Clinical evidence is expensive and slow to generate. Wherever possible, the evidence strategy is designed to answer several legitimate questions at once: regulatory compliance, clinical adoption, reimbursement, publication and product development.
European depth, international collaboration
Regulatory and market-access work is centred on Germany and Europe, including the EU Medical Device Regulation, the In Vitro Diagnostic Medical Devices Regulation and relevant interfaces with the EU AI Act.
Medical strategy, study design, clinical concept development, due diligence and specialist work in pathology and imaging can support organisations internationally.
Senior involvement throughout
Engagements are led by Dr Karl Quint, a physician and scientist with experience in pathology, oncology, translational research, medical technology, digital health and European innovation programmes. Where execution requires a CRO, quality-management provider, statistician, health economist or other specialist, roles are defined explicitly and the right partners are integrated.
Why this architecture fits the market now
Europe combines a large and innovative medical-technology sector with a difficult path from research to routine use. The European Commission's current policy work identifies fragmentation, access to finance, market uptake and the transition from laboratory to market as continuing weaknesses.
At the same time:
- MDR and IVDR implementation is moving towards simplification and digitalisation, but clinical credibility and patient safety remain central.
- AI-enabled products must align medical-device, AI and evidence requirements.
- The European Health Data Space creates a phased framework for health-data use and exchange, including future cross-border exchange of medical images and laboratory results.
- European health systems face serious workforce constraints; technology must therefore improve the clinical workflow rather than merely add another layer to it.
- European life-sciences policy is directing attention towards multi-country trials, market access and innovation procurement.
The service architecture follows these conditions. Regulation, evidence, market access, adoption, medical leadership, funding and team development are presented as connected decisions rather than separate consulting categories.
Who the services are for
- Medical-device, IVD and digital-health manufacturers
- Startups and scale-ups approaching clinical validation or European market entry
- Established technology companies moving into medical applications
- Hospitals, universities and research institutes developing translational projects
- Investors and corporate teams assessing clinical plausibility, evidence maturity and adoption risk
- Consortia applying for or delivering European health and medical-technology projects
A practical first step
The first engagement should reduce uncertainty before it expands scope. Useful starting points include a clinical-file review, an evidence workshop, an adoption audit, a clinical positioning review, a team-alignment workshop or a proposal review against the scoring criteria.
